Media Contact Information:

Katie Engleman
Pure Communications, Inc.

<< Back to Articles

Igenica Biotherapeutics Awarded SBIR Grant for Next Generation Antibody Drug Conjugate Technology

BURLINGAME, Calif. – August 7, 2014 – Igenica Biotherapeutics, Inc., a company focused on the discovery and development of innovative cancer antibody-drug conjugates (ADCs), announced today the award of a $215,740 Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) to support continued development of its SNAP site-specific ADC linker technology. SNAP technology, named for its speed and ease of use, overcomes the major limitations of current approaches by providing a simple, chemically-driven method for linking any anti-cancer antibody and small molecule cytotoxic drug to produce ADC products with optimal and uniform ratios of drug to antibody.

“Drug companies are aggressively pursuing ADCs as powerful new anti-cancer medicines comprised of a monoclonal antibody, a linker and a payload,” said Mary Haak-Frendscho, Ph.D., chief executive officer of Igenica. “SNAP is a transformative, chemically-driven and broadly applicable technology that will accelerate the development of next-generation cancer therapeutics designed to selectively target cancer cells with potent cytotoxic agents. We are using this platform to strengthen our internal product pipeline and also will make it available to select partners.”

The current generation of ADCs, which are developed using conventional chemistry approaches, offer limited benefits to patients because they are heterogeneous drug mixtures containing variants with sub-optimal pharmaceutical properties. Igenica’s SNAP technology is comprised of a cutting-edge and proprietary linker that yields homogeneous ADCs armed with the optimal quantity of toxin payload to kill cancer cells. This approach should translate to drugs with lower toxicity and higher efficacy for cancer patients.

About Igenica Biotherapeutics

Igenica Biotherapeutics is focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. Igenica is the only biotherapeutic company that fully powers the ADC development spectrum from a patient-based approach to target and functional antibody discovery to the generation and manufacturing of homogeneous ADCs. Igenica’s integrated discovery engine has generated a robust pipeline of site-specific ADC candidates and functional antibodies to address critical needs of cancer patients. Led by a proven team of leaders with expertise in the development of therapeutic antibodies and ADCs, Igenica is funded by a premier group of life science investors including The Column Group, OrbiMed, 5AM Ventures and Third Rock Ventures. For more information, please visit


Katie Engleman
Pure Communications Inc.